Government caps trade margins on non-scheduled anti-cancer medicines at 30% of MRP; patients to save ₹2,500 crore a year
On 8 October 2026, the Government approved capping the margins charged in the supply and sale of non-scheduled anti-cancer drugs at 30% of MRP, expected to cut prices by up to 70% and save cancer patients ₹2,500 crore annually.
Summary
The Department of Pharmaceuticals announced on 8 October 2026 that the Government has approved a cap on trade margins for non-scheduled anti-cancer medicines, limiting them to 30% of the Maximum Retail Price (MRP). The step is expected to reduce prices by up to 70% and save patients about ₹2,500 crore a year; NPPA found an average mark-up of about 170% on such medicines. An expert committee under DGHS will finalise the list and the National Pharmaceutical Pricing Authority (NPPA) will issue the notification. It builds on the February 2019 cap on 42 non-scheduled anti-cancer drugs under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
Key facts
- Decision
- Trade-margin cap on non-scheduled anti-cancer drugs
- Cap
- 30% of MRP
- Expected price cut
- Up to 70%
- Expected savings
- ₹2,500 crore per year
- List to be finalised by
- Expert committee under DGHS
- Notification by
- National Pharmaceutical Pricing Authority (NPPA)
- Average mark-up found
- About 170% (700%+ in some cases)
- Earlier step
- Feb 2019: 42 drugs capped under Para 19, DPCO 2013
Practice MCQs 2 questions
In October 2026, the Government capped the trade margins on non-scheduled anti-cancer medicines at what share of MRP?
Show answer
Correct answer: B — 30%
How much are cancer patients expected to save annually from the October 2026 trade-margin cap on non-scheduled anti-cancer drugs?
Show answer
Correct answer: C — ₹2,500 crore